IGF-1 LR3 Side Effects

Reported IGF-1 LR3 side effects

Acute and Common Hypoglycemia — The primary acute safety concern. Post-injection blood glucose drops can produce shakiness, sweating, confusion, palpitations, and in severe cases loss of consciousness. Mitigation: 30-40g of fast-digesting carbohydrate within 30 minutes of injection; avoid combining with insulin or aggressive carb restriction; test blood glucose during first weeks of dosing. Injection site reactions — Mild erythema and transient itching at SC site. Site rotation minimizes. Mild hunger — From insulin-receptor activation and blood glucose effects, not ghrelin pathway. Less pronounced than with GHRP compounds. Slight warmth or flushing — Occasional, short-lived. Less Common (Early) Jaw/temporomandibular pain — Reported by some users particularly in first weeks; possibly related to growth effects on facial muscles or connective tissue Mild facial puffiness — Water retention and soft-tissue growth Localized muscle soreness at injection site — Occasionally severe in users who inject intramuscularly (IM) rather than SC Transient fatigue — Usually in association with early hypoglycemic episodes Headache — Mild, usually responsive to hydration Dose-Dependent with Chronic Use Peripheral tissue growth / "IGF gut" — Intestinal epithelial hypertrophy produces a distinctive abdominal distension at high cumulative doses. This is an IGF-1 receptor expression phenomenon — the gut lining is highly proliferative and IGF1R-positive, so chronic high-dose IGF-1 LR3 drives measurable gut tissue growth. Reversible with discontinuation but takes weeks to months to fully resolve. Organ enlargement — Liver, spleen, kidneys all express IGF1R. Chronic high-dose use can produce organomegaly detectable on imaging. Most users never develop this at typical bodybuilding doses, but the risk scales with dose and duration. Cardiac hypertrophy — Theoretical concern. The heart responds to IGF-1 signaling; prolonged supraphysiologic exposure could contribute to left ventricular hypertrophy. Generally not clinically significant at typical use patterns but warrants periodic echocardiographic monitoring in long-term users. Lymphoid tissue hypertrophy — Tonsillar enlargement, adenoid hypertrophy, occasionally submandibular lymph node enlargement. Documented in mecasermin pediatric trials; likely applies to IGF-1 LR3 at sufficient dose/duration. Long-term Theoretical Cancer risk — This is the most important theoretical concern. IGF-1 is a pro-mitogenic signal; virtually every malignancy overexpresses IGF1R; elevated IGF-1 is a risk factor for breast, prostate, and colon cancers in epidemiologic studies. Sustained supraphysiologic IGF-1 LR3 signaling has mechanistic plausibility for cancer promotion in users with any pre-existing occult malignancy or strong predisposition. No large-population longitudinal data exists to quantify this risk in performance-dose LR3 users specifically, but the mechanism is well-established and conservative dosing with periodic screening is warranted. Acromegalic changes — Soft tissue growth effects (enlarged hands/feet, facial bone remodeling) with very chronic high-dose use approaching acromegaly-like patterns. More common in exogenous HGH abuse but possible with sustained IGF-1 LR3. Diabetes risk — Chronic insulin-receptor cross-activation could theoretically contribute to beta-cell exhaustion or insulin resistance patterns over very long timescales. Serious but Rare Severe hypoglycemia with loss of consciousness — Usually preventable with appropriate carbohydrate management Symptomatic organomegaly — Abdominal fullness, early satiety, or imaging abnormalities Unexpected new growth of pre-existing moles or tumors — Immediate discontinuation and oncology evaluation Signs You Need to Stop Any unexplained new or changing mass, lymphadenopathy, or pigmented lesion Symptomatic abdominal distension or early satiety (suggesting gut/organ growth) Persistent fasting glucose or HbA1c elevation New chest pain, shortness of breath, or cardiovascular symptoms Any signs of organomegaly on physical exam or imaging Disproportionate lymphoid tissue enlargement (large tonsils, adenoids, or nodes)

When to continue, reduce, or stop IGF-1 LR3

IGF-1 LR3 contraindications

IGF-1 LR3 is contraindicated or requires strict caution in: Absolute contraindications: Active malignancy, any type — IGF-1 is a pro-mitogenic signal; IGF1R is expressed on virtually all cancer cells; supraphysiologic IGF-1 exposure in the presence of malignant cells has mechanistic cancer-promotion risk Strong family history of breast, prostate, colon, or other hormonally-responsive cancers — elevated IGF-1 is an epidemiologic risk factor for these cancers Active proliferative retinopathy — IGF-1 drives retinal neovascularization Pregnancy and lactation — no safety data; theoretical fetal growth effects Pediatric or adolescent use without specialist supervision — growth plate and organ development concerns Hypoglycemia unawareness or severe hypoglycemic episodes in history — acute safety risk is unacceptable Known hypersensitivity to IGF-1 LR3 or IGF-1 analogs Strong relative cautions: Diabetes mellitus (any type) — hypoglycemia risk is significantly elevated and the condition itself involves disrupted IGF-1/insulin signaling Prior history of any cancer, even if treated and disease-free — specialist supervision required if used at all Active or treated pituitary adenoma — IGF-1 axis disruption concerns Organomegaly (hepatomegaly, splenomegaly) — will worsen Active intestinal disease (Crohn's, ulcerative colitis, severe diverticular disease) — gut growth effects may worsen symptoms Severe cardiovascular disease — cardiac hypertrophy concerns Sleep apnea (untreated) — soft-tissue growth may worsen airway obstruction Relative cautions (monitor closely): Borderline glucose tolerance or HbA1c Any history of benign tumor/adenoma (pituitary, adrenal, parathyroid) Strong family history of colon polyps — colonoscopy surveillance essential Users on immunosuppressants — theoretical concern about IGF-1 effects on cancer surveillance Users with low-grade chronic inflammation or elevated hs-CRP — IGF-1 may modulate inflammation in complex ways Users with prior skin cancer (even non-melanoma) — dermatology surveillance required Drug interactions (dangerous): Insulin (exogenous): Compounded hypoglycemia; potentially life-threatening combination Sulfonylureas (glipizide, glyburide): Compounded hypoglycemia Meglitinides (repaglinide): Compounded hypoglycemia Mecasermin (Increlex): Redundant; both IGF1R agonists; excessive IGF1R activation Drug interactions (manage): Corticosteroids (high-dose prednisone, dexamethasone): Pharmacodynamic antagonism Aromatase inhibitors (letrozole, anastrozole): May modify IGF-1 signaling indirectly Statins: Some evidence of IGF-1 effects modulation Thyroid hormone: Thyroid status affects IGF-1 receptor sensitivity Discontinuation triggers (immediate): Any new or growing skin lesion, mass, or lymphadenopathy Unexplained weight loss Symptomatic abdominal distension, early satiety, or imaging abnormality Persistent fasting glucose >110 mg/dL despite appropriate carb management New chest pain, shortness of breath, or other cardiovascular symptoms Facial or extremity changes suggesting acromegalic growth Any severe hypoglycemic episode despite appropriate carb intake Strong family cancer history revealed after starting use

Why vendor quality drives IGF-1 LR3 side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

IGF-1 LR3 side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .